Dual Mtor1/2 Inhibitor Sapanisertib (TAK-228) in Combination with Weekly Paclitaxel in Patients with Previously Treated Metastatic Urothelial Carcinoma: a Phase II Open-Label Study.
Clinical Genitourinary Cancer（2024）
Key words
advanced urothelial cancer,mTOR inhibitors,biomarkers,chemotherapy,pretreated
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined